A look at Dr Malcolm Brenner's work on virus specific T cell therapies
At ASCO-SITC this weekend there was some compelling new scientific data highlighting subsets of patients who might be eligible for cancer immunotherapy, including novel combination approaches.
6 key trends and highlights of note from the inaugural ASCO-SITC meeting in Orlando, Florida
A look at another surprising factor that might affect efficacy of cancer immunotherapy and checkpoint blockade.
After JAK1/2 upregulation and PTEN loss, a third mechanism of resistance to checkpoint blockade has been identified. We discuss the issues around this latest challenge...